Extended Data Fig. 4: CDO1 expression in human leukaemia microenvironment.
From: Taurine from tumour niche drives glycolysis to promote leukaemogenesis
a, Kaplan-Meier curves of human leukaemia patients with high (<9.32, n = 80) or low (≥9.32, n = 81) LDLR expression (TCGA-LAML; Xena Browser; log-rank test). b, Normalized LDLR expression in CD34+ cells from human bcCML, AML, or normal BM (n = 7 normal BM, n = 10 bcCML, n = 11 AML; central line, box, and whiskers represent median, interquartile range or IQR, minimum/maximum within 1.5*IQR respectively; DESeq2 implemented Wald test). c, d, Experimental strategy (c) and relative Apoe expression (d) in MSCs transduced with shRNAs targeting LacZ or Apoe (mean ± s.d.; n = 3 technical replicates per cohort). e,f, Number of live leukaemia cells (e) and their colony forming ability (CFU) (f) post co-culture with MSCs (mean ± s.e.m.; e, n = 8 independent culture wells; f, n = 6 independent culture wells, data combined from two independent experiments; unpaired two-tailed Student’s t-test). g, Slc6a6 expression in KLS cells infected with BCR-ABL and NUP98-HOXA9 (BA-NH) oncogenes for 48 h (mean ± s.d.; n = 3 technical replicates per cohort). h, Taurine biosynthesis pathway. i, Dot plot of Cdo1 and Csad expression during disease progression. j, UMAP plot of CDO1 and CSAD expression in normal human BM23. k, UMAP plot of microenvironmental cells in three human MDS or AML BM aspirates. l, UMAP plot of CDO1 and CSAD in human MDS and AML BM aspirates. m-p, Representative IHC images and quantification of Osterix expression in matched human BM biopsies at MDS diagnosis and AML transformation (m, n) or AML diagnosis and relapse (o,p) (n = 5 independent patients per cohort; each colour represents a patient sample; two-tailed ratio paired t-test). The mouse image in c is adapted from ref. 6, Springer Nature America.
